Skip to content
Study details
Enrolling now

Acetazolamide for Treatment Resistant Schizophrenia

Vishwajit Nimgaonkar, MD PhD
NCT IDNCT04887792ClinicalTrials.gov data as of Apr 2026
Phase

Phase 1/2

Target enrollment

60

Study length

about 4.9 years

Ages

18–55

Locations

1 site in PA

What this study is about

Researchers are testing whether acetazolamide helps people with schizophrenia who haven't responded well to other treatments. It involves comparing acetazolamide to a placebo (an inactive pill). The trial will last about 1793 days and involve approximately 60 participants.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take Acetazolamide
  • 2.Take Placebo

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Injection / IVInjection / IV

How treatment is administered

Treatment Assignment
Randomized & Blinded

You may get a placebo/standard care, and you won't know which.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

acetazolamide

Drug routes

injection, intravenous

Endpoints

Primary: Change in positive symptoms

Secondary: Cognition, Measure of satisfaction with one's Quality of Life (Quality of Life Scale/QOLS)

Body systems

Psychiatry / Mental Health